Chemotherapy improves low performance status lung cancer patients

European Respiratory Journal

Volumn 30, Issue 6, 2007, Pages 1186-1192

  Sculier, J P ^a   Lafitte, J J ^e   Paesmans, M ^a   Lecomte, J ^c   Alexopoulos, C G ^h   Van Cutsem, O ^d   Giner, V ⁱ   Efremidis, A ^h   Berchier, M C ^f   Collon, T ^g   Meert, A P ^a   Scherpereel, A ^e   Ninane, V ^b   Koumakis, G ^h   Vaslamatzis, M M ^h   Leclercq, N ^a   Berghmans, T ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c Centre Hospitalier Universitaire de Charleroi   (Belgium)

^d Clinique St Luc Bouge   (Belgium)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Hopital de Hayange   (France)

^g CHI Le Raincy   (France)

^h SAINT SAVVAS HOSPITAL   (Greece)

ⁱ HOSPITAL DE SAGUNTO   (Spain)

Author keywords

Cancer research; Chemotherapy; Nonsmall cell lung cancer; Performance status

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG FATALITY; FEMALE; HEALTH STATUS; HEART ARREST; HEART FAILURE; HEART INFARCTION; HUMAN; INFECTION; INTESTINE ISCHEMIA; LUNG EMBOLISM; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; STOMACH HEMORRHAGE; STOMACH PERFORATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; IFOSFAMIDE; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 38849117144     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00034507     Document Type: Article

References (24)

1. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4: 702-709.
2. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13: 1221-1230.
3. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005; 23: 175-183.
4. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage nonsmall-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
5. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005; 23: 3125-3137.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
7. Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001; 92: 2639-2647.
8. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
9. Langer C, Lilenbaum R. Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer. Semin Oncol 2004; 31: Suppl. 11, 8-15.
10. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190-196.
11. Sculier JP, Lafitte JJ, Paesmans M, et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 2000; 83: 1128-1135.
12. Sculier JP, Paesmans M, Lafitte JJ, et al. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol 1999; 10: 295-303.
13. Borges M, Sculier JP, Paesmans M, et al. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC). Lung Cancer 1996; 16: 21-33.
14. Sculier JP, Lafitte JJ, Lecomte J, et al. A three-arm phase III: randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002; 13: 874-882.
15. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol 2004; 15: 399-409.
16. Machin D, Campbell MJ. Statistical Tables for the Design of Clinical Trials. Oxford, Blackwell Scientific Publications, 1987.
17. European Lung Cancer Working Party. www.elcwp.org. Date last accessed: October 25, 2007. Date last updated: May 30, 2007.
18. Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination chemotherapy? Ann Oncol 2001; 12: 1667-1670.
19. Stinchcombe TE, Choi J, Schell MJ, et al. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer 2006; 51: 237-243.
20. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
21. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59: 828-836.
22. Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007; 25: 418-423.
23. Kosmidis PA, Dimopoulos M, Syrigos K, et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomised phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007; 2: 135-140.
24. Baka S, Ashcroft L, Anderson H, et al. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤70) and advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 2136-2144.